PERTH, Australia – With the launch of its lead product, Scenesse (afamelanotide), in the U.S. and Europe, Melbourne-based Clinuvel Pharmaceuticals Ltd. is expanding its global footprint and widening its pipeline as it opens a new R&D center in Singapore and builds up its franchise in photo medicine.
PERTH, Australia – With the launch of its lead product, Scenesse (afamelanotide), in the U.S. and Europe, Melbourne-based Clinuvel Pharmaceuticals Ltd. is expanding its global footprint and widening its pipeline as it opens a new R&D center in Singapore and builds up its franchise in photo medicine.
LONDON – After 17 years of patient toil, Lytix Biopharma AS has landed the first commercial endorsement of its oncolytic peptide platform, agreeing to a potential $113.5 million deal in which Verrica Pharmaceuticals Inc. will develop the lead product, LTX-315, as a transdermal treatment for skin cancer.
